Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
Ardelyx (ARDX) has announced its upcoming participation at TD Cowen's 45th Annual Health Care Conference. The company's management will deliver a presentation on Monday, March 3, 2025, at 9:50am ET in Boston.
The presentation will be accessible via live webcast through the Events and Presentations page on Ardelyx's investor relations website. Interested parties can view a replay of the panel presentation on the company's website for 30 days following the event.
Ardelyx is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines addressing significant unmet medical needs.
Ardelyx (ARDX) ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. La direzione dell'azienda presenterà un intervento lunedì 3 marzo 2025, alle 9:50 ET a Boston.
La presentazione sarà accessibile tramite webcast dal vivo attraverso la pagina Eventi e Presentazioni del sito web delle relazioni con gli investitori di Ardelyx. Le parti interessate potranno visualizzare una registrazione della presentazione del panel sul sito dell'azienda per 30 giorni dopo l'evento.
Ardelyx è un'azienda biofarmaceutica focalizzata sulla scoperta, sviluppo e commercializzazione di medicinali innovativi e di prima classe che affrontano significative esigenze mediche insoddisfatte.
Ardelyx (ARDX) ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud de TD Cowen. La dirección de la empresa realizará una presentación el lunes 3 de marzo de 2025, a las 9:50 am ET en Boston.
La presentación estará disponible a través de una transmisión en vivo en la página de Eventos y Presentaciones del sitio web de relaciones con inversionistas de Ardelyx. Las partes interesadas podrán ver una repetición de la presentación del panel en el sitio web de la empresa durante 30 días después del evento.
Ardelyx es una empresa biofarmacéutica centrada en descubrir, desarrollar y comercializar medicamentos innovadores de primera clase que aborden necesidades médicas significativas no satisfechas.
Ardelyx (ARDX)는 TD Cowen 제45회 연례 건강 관리 컨퍼런스에 참석할 예정임을 발표했습니다. 회사 경영진은 2025년 3월 3일 월요일 오전 9시 50분 ET에 보스턴에서 발표를 진행할 예정입니다.
발표는 Ardelyx의 투자자 관계 웹사이트의 이벤트 및 발표 페이지를 통해 실시간 웹캐스트로 접근할 수 있습니다. 관심 있는 분들은 행사 후 30일 동안 회사 웹사이트에서 패널 발표의 재생을 볼 수 있습니다.
Ardelyx는 중요한 의료 요구를 충족하는 혁신적이고 최초의 약물을 발견, 개발 및 상용화하는 데 중점을 둔 생명공학 제약 회사입니다.
Ardelyx (ARDX) a annoncé sa prochaine participation à la 45ème Conférence Annuelle sur la Santé de TD Cowen. La direction de l'entreprise présentera une intervention le lundi 3 mars 2025, à 9h50 ET à Boston.
La présentation sera accessible via un webinaire en direct sur la page Événements et Présentations du site web des relations investisseurs d'Ardelyx. Les parties intéressées pourront visionner un replay de la présentation du panel sur le site de l'entreprise pendant 30 jours après l'événement.
Ardelyx est une entreprise biopharmaceutique axée sur la découverte, le développement et la commercialisation de médicaments innovants de première classe répondant à des besoins médicaux non satisfaits importants.
Ardelyx (ARDX) hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Das Management des Unternehmens wird am Montag, den 3. März 2025, um 9:50 Uhr ET in Boston eine Präsentation halten.
Die Präsentation wird über einen Live-Webcast auf der Seite für Veranstaltungen und Präsentationen der Investor-Relations-Website von Ardelyx zugänglich sein. Interessierte Parteien können die Wiederholung der Podiumsdiskussion 30 Tage nach der Veranstaltung auf der Website des Unternehmens ansehen.
Ardelyx ist ein biopharmazeutisches Unternehmen, das sich auf die Entdeckung, Entwicklung und Vermarktung innovativer, erstklassiger Medikamente konzentriert, die bedeutende unerfüllte medizinische Bedürfnisse ansprechen.
- None.
- None.
WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen’s 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50am ET in Boston.
To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.
About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
When is Ardelyx (ARDX) presenting at the TD Cowen Health Care Conference 2025?
How can investors watch Ardelyx's (ARDX) TD Cowen conference presentation?
How long will the replay of ARDX's TD Cowen conference presentation be available?
What is the focus of Ardelyx's (ARDX) business according to the conference announcement?
